Session Details

S003 Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfall for the General Dermatologist

Fri, Mar 27, 9:00 AM - 12:00 PM
Mile High 4A
3 CME Available Symposium Upcoming
View Map

DESCRIPTION

A case-based approach will be utilized to describe practical clinical scenarios that will enable the resident or general dermatologist to appropriately diagnose and manage patients with cutaneous lupus erythematosus and dermatomyositis. The importance of a thorough and intentional clinical examination will be emphasized to help participants build confidence in accurately diagnosing these relatively rare and often challenging to diagnose conditions. Participants will learn to develop treatment algorithms incorporating typical modalities such as sun protection, topical therapies, and antimalarials, as well as other systemic medications. The evidence for the effectiveness of these agents and their safe use in adults and children will be reviewed. Participants will be able to identify when to initiate systemic immunosuppressive therapy and/or refer to other specialists. Participants will also develop a strategy to appropriately work-up these potentially systemic conditions.

LEARNING OBJECTIVES

1.

Utilize clinical examination to aid in accurate diagnosis of patients with cutaneous lupus erythematosus and dermatomyositis.

2.

Develop a treatment strategy for cutaneous lupus and cutaneous dermatomyositis that incorporates modalities including sun protection, topical therapies, and systemic medications.

3.

Describe associated systemic complications of cutaneous lupus and dermatomyositis and screen appropriately for them.

DIRECTOR

Alisa Femia, MD, FAAD

Alisa Femia, MD, FAAD

SPEAKER

Christopher T Richardson, PhD, MD, FAAD

Christopher T Richardson, PhD, MD, FAAD

DISCLOSURES

Alisa Femia, MD, FAAD

No financial relationships exist with ineligible companies.

Christopher T Richardson, PhD, MD, FAAD

AstraZeneca – Investigator(Grants/Research Funding); Biogen – Advisory Board(Fees); Immunovant – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Priovant – Advisory Board(Honoraria); Ribon Therapeutics – Investigator(Grants/Research Funding);